(Circulation. 2005;111:44-50.)
© 2005 American Heart Association, Inc.
Coronary Heart Disease |
-Protein Kinase C Activation From Ischemia
-Protein Kinase C-Activating Peptide
From the Department of Molecular Pharmacology, Stanford University School of Medicine (K.I., R.B., D.M.-R.), and Department of Cardiovascular Medicine, Stanford University (F.I.), Stanford, Calif.
Correspondence to Daria Mochly-Rosen, Department of Molecular Pharmacology, 269 Campus Dr, 3145 CCSR, Stanford University School of Medicine, Stanford CA 94305-5174. E-mail mochly{at}stanford.edu
Received July 24, 2004; revision received September 10, 2004; accepted September 30, 2004.
Background We previously showed that a selective activator peptide of
-protein kinase C (PKC), 
RACK, conferred cardioprotection against ischemia-reperfusion when delivered ex vivo before the ischemic event. Here, we tested whether in vivo continuous systemic delivery of 
RACK confers sustained cardioprotection against ischemia-reperfusion in isolated mouse hearts and whether 
RACK treatment reduces infarct size or lethal arrhythmias in porcine hearts in vivo.
Methods and Results After 
RACK was systemically administered in mice either acutely or continuously, hearts were subjected to ischemia-reperfusion in an isolated perfused model. Whereas 
RACK-induced cardioprotection lasted 1 hour after a single intraperitoneal injection, continuous treatment with 
RACK induced a sustained preconditioned state during the 10 days of delivery. There was no desensitization to the therapeutic effect, no downregulation of
PKC, and no adverse effects after sustained 
RACK delivery. Porcine hearts were subjected to ischemia-reperfusion in vivo, and 
RACK was administered by intracoronary injection during the first 10 minutes of ischemia. 
RACK treatment reduced infarct size (34±2% versus 14±1%, control versus 
RACK) and resulted in fewer cases of ventricular fibrillation during ischemia-reperfusion (87.5% versus 50%, control versus 
RACK).
Conclusions The
PKC activator 
RACK induced cardioprotection both in vivo and ex vivo, reduced the incidence of lethal arrhythmia during ischemia-reperfusion, and did not cause desensitization or downregulation of
PKC after sustained delivery. Thus, 
RACK may be useful for patients with ischemic heart disease. In addition, the 
RACK peptide should be a useful pharmacological agent for animal studies in which systemic and sustained modulation of
PKC in vivo is needed.
Key Words: arrhythmia ischemia ischemic preconditioning peptides protein kinase C
This article has been cited by other articles:
![]() |
S. S. Palaniyandi, L. Sun, J. C. B. Ferreira, and D. Mochly-Rosen Protein kinase C in heart failure: a therapeutic target? Cardiovasc Res, May 1, 2009; 82(2): 229 - 239. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Inagaki, T. Koyanagi, N. C. Berry, L. Sun, and D. Mochly-Rosen Pharmacological Inhibition of {epsilon}-Protein Kinase C Attenuates Cardiac Fibrosis and Dysfunction in Hypertension-Induced Heart Failure Hypertension, June 1, 2008; 51(6): 1565 - 1569. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. H. Korzick, J. C. Kostyak, J. C. Hunter, and K. W. Saupe Local delivery of PKC{varepsilon}-activating peptide mimics ischemic preconditioning in aged hearts through GSK-3beta but not F1-ATPase inactivation Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2056 - H2063. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Khaliulin, S. J. Clarke, H. Lin, J. Parker, M.-S. Suleiman, and A. P. Halestrap Temperature preconditioning of isolated rat hearts - a potent cardioprotective mechanism involving a reduction in oxidative stress and inhibition of the mitochondrial permeability transition pore J. Physiol., June 15, 2007; 581(3): 1147 - 1161. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Anderson Multiple downstream proarrhythmic targets for calmodulin kinase II: Moving beyond an ion channel-centric focus Cardiovasc Res, March 1, 2007; 73(4): 657 - 666. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Ikeno, K. Inagaki, M. Rezaee, and D. Mochly-Rosen Impaired perfusion after myocardial infarction is due to reperfusion-induced {delta}PKC-mediated myocardial damage Cardiovasc Res, March 1, 2007; 73(4): 699 - 709. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Apple, J. E. McLean, C. E. Squires, B. Schaeffer, J. A. Sample, R. L. Murphy, A. M. Deschamps, A. H. Leonardi, C. M. Allen, J. W. Hendrick, et al. Differential Effects of Protein Kinase C Isoform Activation in Endothelin-Mediated Myocyte Contractile Dysfunction With Cardioplegic Arrest and Reperfusion Ann. Thorac. Surg., August 1, 2006; 82(2): 664 - 671. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D. T. Costa, R. Jakob, C. L. Costa, K. Andrukhiv, I. C. West, and K. D. Garlid The Mechanism by Which the Mitochondrial ATP-sensitive K+ Channel Opening and H2O2 Inhibit the Mitochondrial Permeability Transition J. Biol. Chem., July 28, 2006; 281(30): 20801 - 20808. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Mukherjee, K. A. Apple, C. E. Squires, B. S. Kaplan, J. E. McLean, S. M. Saunders, R. E. Stroud, and F. G. Spinale Protein Kinase C Isoform Activation and Endothelin-1 Mediated Defects in Myocyte Contractility After Cardioplegic Arrest and Reperfusion Circulation, July 4, 2006; 114(1_suppl): I-308 - I-313. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z.-Q. Zhao and J. Vinten-Johansen Postconditioning: Reduction of reperfusion-induced injury Cardiovasc Res, May 1, 2006; 70(2): 200 - 211. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Inagaki, E. Churchill, and D. Mochly-Rosen Epsilon protein kinase C as a potential therapeutic target for the ischemic heart Cardiovasc Res, May 1, 2006; 70(2): 222 - 230. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Yamamura, C. Steenbergen, and E. Murphy Protein kinase C and preconditioning: role of the sarcoplasmic reticulum Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2484 - H2490. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Bright and D. Mochly-Rosen The Role of Protein Kinase C in Cerebral Ischemic and Reperfusion Injury Stroke, December 1, 2005; 36(12): 2781 - 2790. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |